Could Bausch Health Companies Inc. (BHC) Change Direction After Today’s Significant Increase?

The stock of Bausch Health Companies Inc. (NYSE:BHC) is a huge mover today! The stock increased 4.03% or $1.03 during the last trading session, reaching $26.52. About 5.34M shares traded or 26.90% up from the average. Bausch Health Companies Inc. (NYSE:BHC) has risen 58.45% since May 8, 2018 and is uptrending. It has outperformed by 54.08% the S&P500.
The move comes after 9 months positive chart setup for the $9.31 billion company. It was reported on May, 8 by Barchart.com. We have $28.38 PT which if reached, will make NYSE:BHC worth $651.49M more.

Analysts await Bausch Health Companies Inc. (NYSE:BHC) to report earnings on August, 6. They expect $1.03 EPS, up 10.75 % or $0.10 from last year’s $0.93 per share. BHC’s profit will be $361.47 million for 6.44 P/E if the $1.03 EPS becomes a reality. After $1.03 actual EPS reported by Bausch Health Companies Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Bausch Health Companies Inc. (NYSE:BHC) Ratings Coverage

Among 2 analysts covering Bausch Health Companies (NYSE:BHC), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Bausch Health Companies had 2 analyst reports since March 20, 2019 according to SRatingsIntel. Bank of America maintained it with “Underperform” rating and $18 target in Wednesday, March 20 report.

More notable recent Bausch Health Companies Inc. (NYSE:BHC) news were published by: Seekingalpha.com which released: “Bausch Health: Now Offense – Seeking Alpha” on February 21, 2019, also Schaeffersresearch.com with their article: “Dow Futures Slide 445 Points as Trump Tweets Reignite Trade Tensions – Schaeffers Research” published on May 06, 2019, Seekingalpha.com published: “Synergy Pharma gets court OK to sell assets to Bausch; shares +4.7% – Seeking Alpha” on March 01, 2019. More interesting news about Bausch Health Companies Inc. (NYSE:BHC) were released by: Bizjournals.com and their article: “With an assist from Bausch Health, Dova to add 100 sales professionals to market gastro drug – Triangle Business Journal” published on October 01, 2018 as well as Seekingalpha.com‘s news article titled: “Bausch Health in-licenses autoimmune candidate from Mitsubishi Tanabe – Seeking Alpha” with publication date: April 25, 2019.

Bausch Health Companies Inc. develops, makes, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company has market cap of $9.31 billion. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. It currently has negative earnings. The firm also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.